School of Medicine


Showing 1-10 of 66 Results

  • Karim Sallam, MD

    Karim Sallam, MD

    Assistant Professor of Medicine (Cardiovascular Medicine)

    BioKarim Sallam, MD, is trained in Cardiovascular Medicine and Advanced Heart Failure.

  • Darren Salmi

    Darren Salmi

    Clinical Associate Professor, Pathology

    Current Research and Scholarly InterestsCardiovascular pathology, congenital heart disease, autopsy, medical education

  • Jacinda Sampson

    Jacinda Sampson

    Clinical Professor, Adult Neurology

    BioDr. Jacinda Sampson received her MD and a PhD in biochemistry from University of Alabama at Birmingham, and completed her neurology residency and neurogenetics fellowship at the University of Utah. She served at Columbia University Medical Center prior to joining Stanford University Medical Center in 2015. Her areas of interest include myotonic dystrophies, Duchenne muscular dystrophy, and neurogenetic disorders such as neurofibromatosis, hereditary spastic paraparesis, spinocerebellar ataxia, among others. She is interested in clinical trials for treatment of neurogenetic disorders, and in the clinical application of next-generation genomic sequencing to genetic testing.

  • Fabian Sanchis Gomar

    Fabian Sanchis Gomar

    Instructor, Cardiovascular Institute

    BioFabian Sanchis-Gomar, MD, PhD, is a physician-scientist and Instructor at the Stanford Cardiovascular Institute. His research spans preventive cardiology, cardiovascular physiology, arrhythmias, and cardiometabolic medicine, with a common aim: understanding how physiological, metabolic, and lifestyle factors shape cardiovascular risk, adaptation, and disease. He has authored more than 370 articles in international peer-reviewed journals.

    In preventive cardiology, his work addresses physical activity, cardiorespiratory fitness, and longevity; obesity and metabolic syndrome; cardiovascular biomarkers; and the role of exercise and fitness assessment in heart failure, including heart failure with preserved ejection fraction. More recently, he has studied the cardiovascular implications of obesity pharmacotherapy, particularly the preservation of skeletal and cardiac muscle during GLP-1 receptor agonist treatment.

    In arrhythmia research, he helped characterize atrial fibrillation in endurance athletes as a distinct clinical phenotype and has contributed to studies of arrhythmogenic cardiomyopathy, wearable-based rhythm detection, and subcutaneous ICD implantation. His earlier work examined exercise-induced cardiac remodeling, aging, sarcopenia, and oxidative stress, and he co-edited a reference volume on the cardiovascular consequences of COVID-19.

    He is now building a mechanistic-to-translational research program on how incretin-based therapies influence cardiac electrophysiology and arrhythmia susceptibility, combining real-world clinical data with human iPSC-derived cardiomyocyte models.

    A second emerging line addresses lipoprotein(a) [Lp(a)], the most powerful inherited driver of premature atherosclerotic disease and aortic valve calcification, and one that remains largely untreated in clinical practice. Building on his published work on Lp(a) risk management and its relationship with mortality, he is developing a research program aimed at defining how the molecular features of Lp(a) particles govern receptor engagement, vascular signaling, and clearance, and whether circulating Lp(a) can be redirected toward hepatic degradation.

    Dr. Sanchis-Gomar earned his MD and his PhD in Physiology (summa cum laude) at the University of Valencia, Spain, and completed postdoctoral training at NYU Langone Health and the Stanford Inherited Arrhythmia Clinic.

  • Alexander Tarlochan Singh Sandhu

    Alexander Tarlochan Singh Sandhu

    Affiliate, Med/Center for Digital Health (CDH)

    BioAlex Sandhu, MD, MS is a cardiologist with a special interest in the care of patients with advanced heart failure. He graduated from the seven-year combined BA-MD program at Northwestern with a focus on economics and mathematics. He completed an internal medicine residency at Stanford University, spending 16 weeks at Makerere Hospital in Uganda as part of the Global Health track. He subsequently earned a Masters in Health Services Research at Stanford while acting as a fellow in health services research at the Palo Alto VA and Stanford's Center for Health Policy/Primary Care and Outcomes Research. Next, he completed fellowships in cardiology and advanced heart failure and transplant at Stanford before joining the faculty as an Assistant Professor in Stanford Cardiology and the Stanford Prevention Research Center.

    Alex is now an active clinician and clinical researcher who focuses on the implementation of high-value preventive strategies, comparative effectiveness, innovative clinical trial design, and health economics. He is passionate about testing patient-centered implementation strategies to bring meaningful improvements to patients’ lives and prevent disease morbidity. He is involved in several clinical trials including the K-23 funded PRO-HF (patient-centered quality of life assessments), DOT-HF (digital health study for HF patient activation), a CAC notification pilot trial (patient-centered coronary artery calcification notification), and PHARM-HF (testing strategies to improve HF management by pharmacists).

    In his free time, he enjoys playing soccer as well as entertaining and being entertained by his joyful kids, Kyle, Tyler, and Kira.